Data di Pubblicazione:
2020
Citazione:
Biotechnology Approaches for the Treatment of Dyslipidemia / C. Parolini. - In: CARDIOVASCULAR DRUGS AND THERAPY. - ISSN 0920-3206. - (2020 Jun 09). [Epub ahead of print] [10.1007/s10557-020-07017-6]
Abstract:
Background: Despite advances in the development of lipid-lowering therapies, clinical trials have shown that a significant residual risk of cardiovascular disease persists. Specifically, new drugs are needed for non-responding or statin-intolerant subjects or patients considered at very high risk for cardiovascular events even though are already on treatment with the best standard of care. Results and Conclusions: Besides, genetic and epidemiological studies and Mendelian randomization analyses have strengthened the linear correlation between the concentration of low-density lipoprotein cholesterol (LDL-C) and the incidence of cardiovascular events and highlighted various novel therapeutic targets. This review describes the novel strategies to reduce the levels of LDL-C, non-HDL-C, triglyceride, apolipoprotein B, and Lp(a), focusing on those developed using biotechnology-based strategies.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Apo(a) antisense oligonucleotides; Evinacumab; LDL-cholesterol; Lipids; PCSK9 antibodies; Volanesorsen
Elenco autori:
C. Parolini
Link alla scheda completa: